Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets

This is a randomized, two-arm, comparative Phase II clinical trial designed to evaluate the difference in intracranial progression-free survival (iPFS) between two treatment strategies, assessed locally. Approximately 158 patients will be randomized in a 1:1 ratio. Will be included patients with pathology proven metastatic NSCLC without an actionable genomic alteration for which there is first line targeted treatment available and active asymptomatic brain metastasis (newly diagnosed or progressive). The primary objective is to compare iPFS between the two arms.

NCT Number	NCT07234877
Lead Sponsor	European Organisation for Research and Treatment of Cancer - EORTC Collaborators: Summit Therapeutics
Conditions	Non Small Cell Lung Cancer
Enrollment	158 participants
Start Date	2026-11
Primary Completion	2032-01 (estimated)
Study Completion	2032-04 (estimated)
Updated on ClinicalTrials.gov	2026-06-04